What it is
This is Adamax in a nasal spray rather than an injection. It comes in an atomizer — a small pump bottle that sprays a measured mist into the nose. Each press of the pump delivers 100 micrograms (mcg). There is no powder to mix and no syringe.
Because the spray is absorbed through the lining of the nose, it never passes through the stomach. That means you do not need an empty stomach to take it.
Very little is documented about the compound itself. What is available covers cycle guidance, dosing time, how fast it starts working, storage, how to use the spray properly, the amount per spray, and a dose range. What Adamax is, what it does, what side effects it might have, and who should not use it have not been established. The injectable Adamax entry on this site is equally sparse, so there is nothing to carry across from it except the dosing arithmetic — which does not transfer between routes anyway.
One gap is worth being clear about: the right cycle length is unknown. Research groups most commonly use 10 to 30 days, and nobody has established whether continued use leads to the body's receptors becoming less responsive.
Adamax delivered intranasally by atomizer at 100 mcg per actuation. No reconstitution step.
Intranasal delivery bypasses the gastrointestinal tract and first-pass hepatic metabolism, and gives access to nose-to-brain transport along the olfactory and trigeminal pathways — the standard rationale for the route with neuroactive compounds. Onset is 20–40 minutes.
No pharmacology, structural information, indication set, adverse effect list, or contraindication list is available. The injectable Adamax entry on this site is equally sparse, so nothing substantive is available to carry across; its reconstitution arithmetic is route-specific and does not transfer.
Two unknowns are explicit: cycle length is not established (10–30 day cycles described as most common among research groups), and receptor desensitisation on continued use has not been determined. That second point is the closest thing to mechanistic information available — it implies a receptor-mediated action without naming a receptor, and no target is asserted here.
Note also that the two Adamax routes carry materially different cycle guidance: 8–12 weeks with a matched washout for the injectable, against 10–30 days here. The difference has not been reconciled.
What it does
This has not been established. No effects have been documented.
What is known about using it: it starts working in 20 to 40 minutes, it is dosed in the morning to early afternoon to avoid disturbing sleep, and you do not need an empty stomach. It is taken every day, either as one dose or split into two.
The timing restriction is the only indirect hint available. Compounds are usually confined to the earlier part of the day because they can keep you awake.
Not established. No pharmacodynamic data is available.
What is specified is kinetic and practical: 20–40 minute onset, morning to early afternoon window attributed explicitly to potential sleep disturbance, no fasted-state requirement, daily administration as a single dose or split across two, and refrigerated storage of the atomizer after use.
The dosing window rationale — avoidance of sleep disturbance — is the only activity signal available, and points to an alerting or stimulatory profile without characterising one. The open question of receptor desensitisation on continued use implies a receptor-mediated mechanism; no target has been identified and none is asserted here.
The dose range is unusually wide for a single line of guidance: 100–600 mcg daily, a sixfold span with no titration steps and no criterion given for placing yourself within it.
Benefits
Evidence grades: what the labels mean
- Human trials Supported by randomised or placebo-controlled human trials.
- Limited human data Some human evidence, such as pilot studies, case reports or observational data, but no controlled trials.
- Animal or lab only Shown in animal or cell studies only; not yet tested in people.
- Anecdotal No published studies; based on user reports or theory.
Each grade reflects the strongest published support for that specific claim, not for the compound as a whole.
- No benefits have been documented. That is an absence of documentation, not evidence either way.Anecdotal
- Onset in 20 to 40 minutes.Anecdotal
- No injection, no powder to mix, and no syringe — the atomizer sprays a fixed 100 mcg.Anecdotal
- It does not have to be taken on an empty stomach, because the spray bypasses the digestive system.Anecdotal
- It can be taken as one dose a day or split into two, so the routine is flexible.Anecdotal
- No benefit or indication data is available. Absence of documentation, not a finding.Anecdotal
- Practical properties: 20–40 minute onset; 100 mcg per actuation with no reconstitution; intranasal delivery bypassing the gastrointestinal tract and first-pass metabolism; once- or twice-daily flexibility within a 100–600 mcg daily range.Anecdotal
Reconstitution and dosing
There is no mixing to do. The atomizer sprays a fixed 100 micrograms (mcg) each time you press it, and the dose range matches it — 1 to 6 sprays is 100 to 600 mcg.
Split each dose between both nostrils as far as you can. Four sprays means two in each nostril, not four in the same one. Splitting spreads the liquid over more of the nose lining, less of it runs down the throat and gets swallowed, and absorption is steadier — at any moment one nostril is usually more blocked than the other, and using both evens that out.
Technique matters a great deal. Do not tilt your head back. Tip your head forward, angle the atomizer towards the outside of your nose — roughly towards the outer corner of your eye on that side — then sniff gently as you spray.
Take it every day, either all at once or split into two doses. Dose in the morning to early afternoon, to avoid it disturbing your sleep. Onset is 20 to 40 minutes. You do not need an empty stomach. Keep the atomizer in the fridge after use.
The right cycle length is not known. Research groups most commonly use 10 to 30 days, and nobody has worked out whether using it continuously makes the body stop responding.
The dose range is very wide — 100 mcg at the bottom, 600 mcg at the top, six times as much — and there is no established rule for choosing within it. Starting at the low end is the cautious reading, though this is not a stated recommendation.
The injectable Adamax entry on this site gives a very different cycle: 8 to 12 weeks, against 10 to 30 days here. The difference has not been explained. Do not carry one route's cycle onto the other.
No reconstitution. Dispense rate is 100 mcg per actuation, consistent with the dose line (1–6 sprays = 100–600 mcg). Titration is stepwise in 100 mcg increments. No fill volume or total mass for the atomizer is stated, so no vial figure is given here and no derivation is possible.
Split every dose between both nostrils. This increases exposed mucosal surface area, reduces runoff into the pharynx and loss to swallowing, and compensates for the nasal cycle, where congestion and mucus make one nostril less absorptive than the other at any given time.
Technique: head tipped forward, never back; atomizer angled laterally towards the outer canthus on the same side; gentle sniff on actuation. Head-back positioning directs solution to the pharynx rather than the olfactory and respiratory mucosa.
Timing: morning to early afternoon, attributed to sleep-disturbance risk. Onset 20–40 minutes. Fasting not required. Storage: refrigerate the atomizer after use.
Daily 100–600 mcg, administered as a single dose or split across two. Note this is one of the few schedules on the site expressed as a daily total rather than per administration — the range is taken either once per day or split between two doses.
Cycle: undetermined. 10–30 day cycles are reported as most common among research groups, and receptor desensitisation on continued use has not been established. The conservative reading follows from that uncertainty.
The sixfold dose span carries no established titration criterion.
Cross-route discrepancy worth flagging: the injectable Adamax entry specifies an 8–12 week cycle with a matched washout, against 10–30 days here. The two have not been reconciled; do not transfer cycle guidance between the routes.
Nasal atomizer — 100 mcg per spray
Cycle: Not established; 10–30 day cycles reported as most common among research groups · Frequency: Daily, as a single dose or split between two doses; morning to early afternoon
| When | Dose | How often |
|---|---|---|
| Daily | 1–6 sprays (100–600 mcg) per day | a daily total, not a per-dose amount — taken once, or split across 2 doses |
Who should avoid it
- No contraindications have been documented. Treat that as missing information, not as clearance for everyone.
- No medicine interactions have been documented, so none have been ruled out. Go through your full medication list with a doctor before starting.
- The standard exclusions for a research compound with no published human safety information — pregnancy, breastfeeding, and use in anyone under 18 — have not been addressed either way.
- Nasal sprays are absorbed through the lining of the nose, so an existing nasal problem — heavy congestion, recent nasal surgery, frequent nosebleeds — is worth raising with a doctor first.
- Nobody knows the right cycle length, or whether the body stops responding to repeated use, and that is itself a reason for caution. The advice in that situation is to dose as conservatively as possible.
- Talk to a doctor before starting.
- No contraindication list has been established. Absent documentation rather than an established safety profile.
- No drug interactions are documented. Nothing has been excluded; concomitant centrally acting medication warrants independent review.
- Pregnancy, lactation, and paediatric use are unaddressed.
- Intranasal absorption depends on mucosal integrity, so nasal pathology, recent sinonasal surgery, or epistaxis history are route-specific considerations that have not been addressed.
- Relevant to exposure limits: cycle length is undetermined and receptor desensitisation on continued use has not been established. The conservative reading — the shorter end of the 10–30 day range and the lower end of the dose span — follows from that uncertainty.
Side effects
- No side effects have been documented. That is an absence of information, not a claim that there are none.
- The one indirect signal: dosing is restricted to the morning and early afternoon to avoid disturbing sleep. So sleep disruption is an implicitly acknowledged possibility.
- Any spray into the nose can irritate the lining — stinging, dryness, a runny nose, or a taste at the back of the throat are common with nasal sprays generally.
- The injectable Adamax entry lists no side effects either, so there is nothing to carry across from it.
- No adverse effect data is available. Absent documentation, not a negative finding.
- Indirect signal: the morning-to-early-afternoon window is explicitly attributed to potential sleep disturbance, so insomnia is an acknowledged liability even though it is not listed as an adverse effect.
- Local intranasal tolerance effects — mucosal irritation, stinging, rhinorrhoea, posterior nasal drip and associated taste — are generic to the route.
- Injection site reactions do not apply to this route, and the injectable Adamax entry carries no adverse effect list to borrow in any case.
User reports
User reports are individual experiences submitted by site visitors. They are not medical advice, are not verified for accuracy, and do not reflect Amino Reference's views. Read the evidence section above and talk to a clinician. Full disclaimer.
Stacking
The same compound as an injection. It is not a partner to run alongside this one — it is the alternative route. If both are used, add up the total taken in a day. Note that the two routes have very different cycle lengths.
Same compound, subcutaneous route, 300–1,000 mcg once daily on a titrated four-step escalation. Duplicative rather than complementary; count total daily exposure across routes, and note the unreconciled cycle-length difference between the two routes.
- No established stacks
No compounds have been documented as combinations with nasal Adamax. The entry above is a cross-reference to the other route on this site, not a stacking recommendation.
No stacking data exists. The route cross-reference above is editorial. With no mechanism characterised for either Adamax route, any combination reasoning would be invention.
Dosing figures have been reviewed and units are recomputed from the stated protocol.